The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus

Lekh N Dahal, Robert N Barker, Frank J Ward*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)


Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by fluctuating levels of immune response hyperactivity, high serum titers of nucleic antigen-specific autoantibodies, and persistent production of type-I interferon (IFN)1 One route to controlling SLE has been to exploit the properties of T cell lymphocyte costimulation inhibitor (CTLA-4), a selective costimulation inhibitor, which suppresses autoantigen-specific T cell response intensity2.

Original languageEnglish
Article number190678
Pages (from-to)302-304
Number of pages3
JournalJournal of Rheumatology
Issue number2
Early online date1 Dec 2019
Publication statusPublished - 1 Feb 2020

Bibliographical note

We are grateful to Dr. Nick Fluck, Dr. Neil Basu, Dr. Lars P Erwig, and Dr. Hazem Youssef for their invaluable support in recruiting patients for the study; Prof. Georgina L. Hold for assistance and interpretation with SNP studies; and Vivien Vaughan for her expertise in recruiting study participants and maintaining ethical documentation.
This work was supported by Arthritis Research UK (Grant no. 19282). F.J. Ward, L.N. Dahal, and R.N. Barker have filed a patent covering the use of the monoclonal antibody targeting the soluble isoform of CTLA-4 as a therapeutic agent. L.N. Dahal and F.J. Ward share joint senior authorship of this article.


Dive into the research topics of 'The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this